Traders should monitor the March 18 data presentation for any signals of tolerability, target engagement, or dose-dependent degradation, which could de-risk ARV-102 and support valuation. Positive signals may catalyze near-term upside, especially given recent insider buying.
ARVN drugs
ARVN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 11 $13.48entry
- T+1 · 8mo ago −7.42%α −5.93% · $12.48
- T+5 · 8mo ago −19.21%α −17.03% · $10.89
- T+20 · 7mo ago −17.14%α −17.66% · $11.17
- T+60 · 6mo ago −42.88%α −54.40% · $7.70
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Arvinas announced that Phase 1 clinical trial data for its investigational Parkinson’s disease drug ARV-102 will be presented at the AD/PD™ 2026 conference. The data will include safety, pharmacokinetic, and pharmacodynamic results from multiple doses in Parkinson’s patients, with a planned Phase 1b trial in progressive supranuclear palsy (PSP) pending regulatory feedback.
Key Facts
- ARV-102 is an oral PROTAC degrader targeting LRRK2, designed to cross the blood-brain barrier.
- Phase 1 data on safety, PK, and PD will be presented at AD/PD™ 2026 on March 18, 2026.
- Arvinas plans to initiate a Phase 1b trial in PSP patients in the first half of 2026, pending regulatory feedback.
- No efficacy data or clinical outcomes were disclosed, only safety and pharmacological profiles.
Financial Impact
No immediate financial impact; data presentation may influence investor sentiment ahead of future trial milestones.
Risk Factors
- Phase 1 data may show limited target engagement or safety concerns, which could delay development.
- No guarantee of regulatory approval to proceed with PSP trial.
- High biotech development risk: clinical setbacks could significantly impact valuation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253623 |
Track record
21 reports on ARVN
6 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +28.62% at T+60 after the Feb 23, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 3, 202613d ago S-3 Bearish 5/10 Entry $7.42 to $6.55 Now $6.77 +8.76% ▲ +11.73% +7.32% vs SPY
- Nov 3, 202613d ago 8-K Bearish 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 4/10 Entry $7.09 to $7.42 Now $6.77 −4.51% ▲ +4.65% +3.00% vs SPY
- Sep 4, 202610w ago 144 Neutral 3/10 Entry $9.08 to $8.76 Now $6.77 −25.44% ▼ −3.52% −3.06% vs SPY
- Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.14 to $8.05 Now $6.77 −16.83% ▼ −1.11% −1.06% vs SPY
- Jun 2, 202623w ago 8-K Bearish 6/10 Entry $7.70 to $7.74 Now $6.77 +12.08% ▼ −0.52% −0.12% vs SPY
- May 12, 202626w ago 8-K Mixed 6/10 No price data
- May 12, 202626w ago 8-K Bullish 7/10 Entry $9.57 to $9.87 Now $6.77 −29.26% ▲ +3.13% +2.56% vs SPY
- May 12, 202626w ago Press Release Bearish 8/10 Entry $9.57 to $9.87 Now $6.77 +29.26% ▼ −3.13% −2.56% vs SPY
- May 8, 202627w ago 144 Neutral 2/10 Entry $9.66 to $9.57 Now $6.77 −29.92% ▼ −0.93% −0.80% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers